John P. Hamill - 30 Jan 2023 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: SrVP/CFO/Prin. Fin&Acctg. Off
Signature: /s/ John P. Hamill
Issuer symbol: APRE
Transactions as of: 30 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 30 Jan 2023, 16:21:51 UTC
Previous filing: 26 Jul 2022
Next filing: 27 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Award	$0	+269,879		$0.000000	269,879	30 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Employee Stock Option (Right to Buy)	Award	$0	+539,758		$0.000000	539,758	30 Jan 2023	Common Stock	539,758	$0.4960	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units which were granted on January 30, 2023, and which will vest and be settled in common stock in three equal, annual installments beginning on January 30, 2024, January 30, 2025, and January 30, 2026, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2	Twenty-five percent of these options vest on January 30, 2024, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Content

These shares represent restricted stock units which were granted on January 30, 2023, and which will vest and be settled in common stock in three equal, annual installments beginning on January 30, 2024, January 30, 2025, and January 30, 2026, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Twenty-five percent of these options vest on January 30, 2024, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.